Login to Your Account

Win 'Won't Move Needle Much'

Tarceva Reprieve? FDA Delay Could Mean Little Either Way

By Randy Osborne

Monday, January 25, 2010
Last week's Tarceva news - unlike the thumbs-down vote by an FDA advisory panel in December - came as little surprise: The action date for a decision on the already-marketed EGFR drug in a new indication, first-line maintenance therapy for non-small-cell lung cancer, has been set back 90 days to April 18.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription